Overview

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Status:
NOT_YET_RECRUITING

Trial end date:
2027-10-15

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.

Phase:

PHASE4

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

rozanolixizumab